Neuroimmunology of Autoimmune Encephalitis: From Antibody-Mediated Pathogenesis to Multidisciplinary Care
PDF (English)

საკვანძო სიტყვები

Neuroinflammatory diseases
Autoimmune encephalitis
Autoantibodies
Neuroimaging
Relapse prevention

როგორ უნდა ციტირება

Mozafari, P., Zehra, S., Athuldoraarachchi, D. C., Mohammad, M., & Vaddempudi, T. C. (2025). Neuroimmunology of Autoimmune Encephalitis: From Antibody-Mediated Pathogenesis to Multidisciplinary Care. ახალგაზრდა მკვლევარები, 3(5), 23–31. https://doi.org/10.52340/jr.2025.03.05.03

ანოტაცია

The complex neuroinflammatory disease known as autoimmune encephalitis (AE) is typified by the generation of autoantibodies that target different central nervous system receptors, proteins, and ion channels. In this review, neuroimmunology of AE is considered, and special attention will be paid to how it is caused, presented in clinical cases, diagnosed, and treated. The most common forms of AE are anti-NMDAR, LGI1 and CASPR2 encephalitis which are all associated with the different autoantibodies and clinical presentation. In paraneoplastic AE, there is the expression of non-paraneoplastic factors, post-infectious factors and mimicry of specific molecular entities that stimulate autoantibody production.  The clinical manifestations of AE include a wide variety of manifestations that can include mental disorders, cognition decline, epileptic disorders, movement, and autonomic dysfunction.  The multi-disciplinary diagnosis is achieved through neuroimaging, electroencephalography, cerebro spinal fluid analysis and autoantibody testing of which the autoantibody testing is the gold standard. Also, Corticosteroids, intravenous immunoglobulins, and plasmapheresis are the first-line immunotherapies of AE; second-line agents are cyclophosphamide and rituximab, which are applied in cases of refractory disease.  Immunotherapy needs to be initiated in an early manner so as to achieve better outcomes and prevent relapses.  Crucial part of management is tumor removal when there is suitability.  To assist patients with regard to quality of life and care, behavioral support, relapse prevention, and long-term monitoring operations are necessary. Since not all patients can obtain complete recovery of their cognitive and motor capacities, this retraces the importance of further developing research and standardizing practices, which is necessary to enhance knowledge and improvement of AE, which cannot be completed without constant research and development of antibody panels. Patient centered care, clinical awareness, and multi-disciplinary care are important in maximizing the outcomes of affected individuals due to this complex neuroimmunological disorder.

https://doi.org/10.52340/jr.2025.03.05.03
PDF (English)

წყაროები

-Hébert J, Muccilli A, Wennberg RA, Tang-Wai DF. Autoimmune encephalitis and autoantibodies: a review of clinical implications. J Appl Lab Med. 2022 Jan 5;7(1):81–98. doi:10.1093/jalm/jfab102.

-Beltrán E, Paunovic M, Gebert D, Cesur E, Jeitler M, Höftberger R, et al. Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis. Acta Neuropathol. 2021 Jan;141(1):67–83. doi:10.1007/s00401-020-02239-2.

-Dalmau J, Bataller L. Neuronal surface antibody-mediated autoimmune encephalitis. Semin Neurol. 2014 Sep;34(4):458–466. doi:10.1055/s-0034-1390394.

-Uy CE, Binks S, Irani SR. Autoimmune encephalitis: clinical spectrum and management. Pract Neurol. 2021 Oct;21(5):412–423. doi:10.1136/practneurol-2020-002567.

-Sanvito F, Pichiecchio A, Paoletti M, et al. Autoimmune encephalitis: what the radiologist needs to know. Neuroradiology. 2024;66(5):653–675. doi:10.1007/s00234-024-03318-x.

-Update on the diagnosis and management of autoimmune encephalitis [Review]. J Clin Neurosci. 2020 Aug;75:8–17.

-Comorbidities and their influence on outcomes and infectious complications in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2025 Jul;[volume(issue)]:[pages].

-Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K, et al. Acute and long-term immune-treatment strategies in anti-LGI1 antibody–mediated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e467. doi:10.1212/NXI.0000000000000467.

-Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDAR autoimmune encephalitis. Ann Neurol. 2014 Apr;75(4):522–536. doi:10.1002/ana.24190.

-Varley JA, Strippel C, Handel A, Irani SR. Autoimmune encephalitis: recent clinical and biological advances. J Neurol. 2023 Aug;270(8):4118–4131. doi:10.1007/s00415-023-11685-3.

-Abboud H, Probasco J, Irani SR, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2017;11:1756285617722347. doi:10.1177/1756285617722347.

-Pillai SC, Hacohen Y, Tantsis E, et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics. 2015 Apr;135(4):e974–e984. doi:10.1542/peds.2014-2702.

-Lee S, Abboud H, Irani SR, Nakajima H, Piquet AL, Pittock SJ, et al. Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab (CIELO). Front Neurol. 2024;15:1437913. doi:10.3389/fneur.2024.1437913.

-Pai V, Kang H, Suthiphosuwan S, Gao A, Mandell D, Shroff M. Autoimmune encephalitis: insights into immune-mediated central nervous system injury. Korean J Radiol. 2024 Sep;25(9):807–823. doi:10.3348/kjr.2023.1307. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11361799/.

-Dalmau J, Graus F. Update on the diagnosis and management of autoimmune encephalitis. J Clin Neurosci. 2023 Jul;102:8–17. doi: 10.1016/j.jocn.2023.04.003. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12021719/

Downloads

Download data is not yet available.